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Abstract
Background:We analyzed the prognostic value of b-type natriuretic peptide (BNP) and sensitive cardiac Troponin (s-cTnI) in
patients with ischemic stroke or transient ischemic attack (TIA) and their significance in predicting stroke aetiology.
Methods: In a prospectively enrolled cohort we measured BNP and s-cTnI levels upon admission. Primary endpoints were
mortality, unfavorable functional outcome and stroke recurrence after 90 days and after 12 months. Secondary endpoint
was cardioembolic aetiology.
Results: In 441 patients BNP but not s-cTnI remained an independent predictor for death with an adjusted HR of 1.2 (95% CI
1.1–1.4) after 90 days and 1.2 (95% CI 1.0–1.3) after one year. The comparison of the Area under Receiver Operating
Characteristic (AUROC) of model A (age, NIHSS) and model B (age, NIHSS, BNP) showed an improvement in the prediction of
mortality (0.85 (95% CI 0.79–0.90) vs. 0.86 (95% CI 0.81–0.92), Log Rank p= 0.004). Furthermore the category free net
reclassification improvement (cfNRI) when adding BNP to the multivariate model was 57.5%, p,0.0001. For the prediction
of functional outcome or stroke recurrence both markers provided no incremental value. Adding BNP to a model including
age, atrial fibrillation and heart failure lead to a higher discriminatory accuracy for identification of cardioembolic stroke
than the model without BNP (AUC 0.75 (95% CI 0.70–0.80) vs. AUC 0.79, (95% CI 0.75–0.84), p = 0.008).
Conclusion: BNP is an independent prognostic maker for overall mortality in patients with ischemic stroke or TIA and may
improve the diagnostic accuracy to identify cardioembolic aetiology.
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Introduction
Several prognostic [1] and some aetiological biomarkers have
been evaluated in ischemic stroke but so far most failed to show
incremental information. Aetiological classification of ischemic
stroke and TIA is critical to discern the best treatment for specific
secondary prevention. In a European population-based study the
highest recurrence rate after stroke or TIA was found among
patient with cardioembolic aetiology when compared to all other
types of aetiology [2]. Therefore, early identification of cardioem-
bolic aetiology of stroke is crucial.
B-type natriuretic peptide (BNP) is a neurohormone secreted
predominantly from the myocardium in response to wall stretch or
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increased intracardiac pressure [3–6]. High BNP levels have been
shown to predict atrial fibrillation within the general population as
well as in stroke patients [7]. BNP levels were associated with
cardioembolic stroke aetiology [8,9]. Furthermore, high plasma
levels of BNP were an independent predictor of short and long-
term mortality [10,11] and of functional outcome at 6 months
after ischemic stroke [12,13]. New published data show that BNP
levels are associated with TIA recurrence after a TIA [14].
However, these data base on a small group of patients and need to
be verified in a larger cohort. Recently, a meta-analysis found that
BNP levels were associated with all cause mortality but not with
functional outcome. The incremental prognostic value concerning
overall mortality, however, was limited. The authors of this meta-
analysis concluded with the remark that further well designed
cohort studies are needed to assess the predictive value of BNP in
stroke patients [15].
Troponin is a highly sensitive and specific marker of myocardial
necrosis and has an important role in the diagnosis of myocardial
infarction [16]. Similar to BNP, also elevated s-cTnI has been
suggested as marker for increased risk of mortality after an acute
stroke [17–19]. However data on Troponin in the setting of stroke
are more spars. To our knowledge, there are no data on the
association of s-cTnI levels and stroke recurrence.
The purpose of this study was, first, to further validate BNP and
s-cTnI as prognostic markers after stroke and TIA and, second, to
evaluate their ability to identify cardioembolic aetiology.
Material and Methods
Study design and setting
The study design of this prospective cohort study has been
described in detail elsewhere (ClinicalTrials. gov number,
NCT00390962) [20]. Briefly, between November 2006 and
November 2007, all consecutive patients (n = 605) presenting at
the emergency department of the University Hospital Basel,
Switzerland, a 660–bed tertiary care hospital, with a suspected
cerebrovascular event were evaluated. All patients presenting with
an ischemic stroke or a TIA were included after obtained written
informed consent from the patient or the patients’ next of kin. We
defined initial ischemic stroke according to the World Health
Organization criteria as an acute focal neurological deficit lasting
longer than 24 hours [21]. TIA was defined accordingly as a
transient episode of neurological dysfunction caused by focal brain
ischemia with symptoms lasting 24 hours or less. Exclusion criteria
were missing informed consent or any diagnosis different from
ischemic stroke or TIA (i.e. stroke/TIA mimics)
The Ethics Committee of Basel, Switzerland, approved the trial
protocol; informed consent was obtained from all patients.
The protocol for this trial and supporting STROBE Checklist
are available as supporting information (see Checklist S1 and
Protocol S1).
Clinical variables
On admission, the following data were collected with a
standardized bed-side interview and complete chart review: vital
signs, co-morbidities as assessed by the Charlson Comorbidity
Index (CCI) adjusted for stroke, medication prior to ischemic
stroke or TIA and cardiovascular risk factors (i.e. age, gender,
smoking habits, history of hypercholesterolemia, hypertension,
diabetes mellitus, previous TIA or stroke, positive family history
for myocardial infarction, stroke or TIA and history of coronary
heart disease).
Severity of stroke was prospectively assessed on admission by a
neurologist certified in the use of the National Institute of Health
Stroke Scale (NIHSS) [22]. Risk stratification for patients with a
TIA was performed according to the ABCD2-score [23].
Stroke aetiology was determined according to the criteria of the
TOAST classification [24], which distinguishes large-artery
atherosclerosis, cardioembolism, small-artery occlusion, other
aetiology and undetermined aetiology. All patients underwent
the necessary diagnostic work-up to classify aetiology according to
the TOAST criteria [24] such as standard 12-lead electrocardi-
ography and at least 24-hour electrocardiography, echocardiog-
raphy and neurosonographic study of the extra- and intracranial
arteries as well as routine laboratory testing.
The 90 days and the 12 months follow-up was performed using
structured telephone interviews from a blinded stroke physician to
assess mortality from any cause, functional outcome using the
modified Rankin Scale (mRS) and recurrent cerebrovascular events.
Blood sampling
In all patients blood samples were obtained on admission within
72 hours from symptom onset. BNP and sensitive cardiac
Troponin T were measured in a batch analysis blinded to
clinicians. After centrifugation, samples were frozen at 270uC
until they were assayed in a blinded fashion in a dedicated core
laboratory. S-cTnI was measured in EDTA-plasma using the
recently refined s-cTnI assay (Abbott-Architect, Abbott Labora-
tories, Abbott Park, IL, USA) [25–27]. For this test, a limit of
detection (LoD) of 0.01 mg/L, a 99th-percentile cut-off of
0.028 mg/L and a coefficient of variation (CV) of ,10% of
0.032 mg/L have been reported by the manufacturer. Three s-
cTnI strata were predefined: below the limit of detection (,
0.01 mg/L, undetectable), detectable but still in the normal range
(0.01–0.027 mg/L), and increased ($0.028 mg/L, above the 99th
percentile of healthy individuals). The concentration of BNP was
measured in EDTA-plasma using the Architect BNP assay (Abbott
Laboratories, Abbott Park, IL, USA). The analytical range as
reported by the manufacturer extends from 15 to 20’000 pg/ml
for the AxSYM assay.
Endpoints
The primary endpoints of this analysis were a) mortality within
90 days and 1 year in stroke as well as TIA patients b), functional
outcome after 90 days and at 1 year in stroke patients, c) stroke or
TIA recurrence within 90 days.
Patients and or their caregivers were questioned by structured
telephone interviews from blinded stroke physicians at 3 months
and 1 year after the index event to assess mortality from any cause,
functional outcome using the modified Rankin Scale (mRS) and
recurrent cerebrovascular events. Poor outcome was defined as
mRS.2 points. A recurrent cerebrovascular event was defined as
an as an acute ischemic lesion in the brain not attributed to
infection, tumor, demyelination or a degenerative neurologic
disease but due to an occlusive vascular disorder. Further criteria
were rapid onset of a focal neurological deficit occurring for at
least 24 hours in conjunction with brain imaging consistent with
acute ischemic stroke. The CT or MRI may either show a new
infarct or no change from the study performed at entry, i.e. the
diagnosis is clinical and does not require CT/MRI confirmation.
The secondary endpoint was cardioembolic aetiology of stroke
diagnosed during hospitalization according to TOAST criteria
[24] by stroke physicians, which were blinded to BNP and
Troponin measurements.
Neuroimaging
CCT was performed in all patients on admission mainly to
exclude intracranial hemorrhage. Additionally MRI was per-
BNP and s-cTnI as Predictive Markers after Stroke/TIA
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formed in 197 (45%) patients on a clinical 1.5 T MR Avant system
(SIEMENS, Erlangen, Germany) using a stroke protocol, includ-
ing T1-, T2-, and diffusion-weighted (DWI) sequences, as well as
apparent diffusion coefficient (ADC) maps and a MR angiogra-
phy. Lesions were ranked into three sizes to represent typical
stroke patterns: (1) small lesion with a volume of less than 10 ml,
(2) medium lesion of 10 to 100 ml and (3) large lesion with a
volume of more than 100 ml [28].
Statistical analysis
Discrete variables are expressed as frequency (percentage),
continuous Gaussian variables as means with standard deviation
SD and non-Gaussian variables as medians with interquartile ranges
[IQR]. Comparisons between groups were made using chi-square
test, Mann-Whitney U test and Kruskal-Wallis test as appropriate.
Univariate Cox Proportional Hazard Analysis was utilized to
compute hazard ratios and 95% confidence intervals (CI) for
potential predictors of death during the follow-up period. All
significant variables with a p-value ,0.001 (i.e. BNP levels, age,
NIHSS, and lesion size) were tested in a multivariate model using
the Forward Stepwise Method to avoid over fitting of the model.
To estimate association of BNP and Troponin with functional
outcome and re-events, we used logistic regression models. In this
analysis we tested all significant variables in the multivariate
analysis with a p-value ,0.05 (i.e. BNP levels, age, NIHSS,
Charlson Comorbidity Index, CRP, heart failure, atrial fibrillation
and lesion size). Due to a greater number of endpoints the risk of
over fitting was minimal. Receiver operating characteristic (ROC)
curves were constructed for different models to assess the
discriminative value in terms of sensitivity and specificity for
mortality, outcome and aetiology. Comparison was made using
the DeLong test [29] and likelihood ratios for nested models as
appropriate. Furthermore we calculated the continuous (category
free) net reclassification improvement (NRI) [30] for the primary
endpoint, i.e. mortality to assess the incremental value of BNP
over the multivariate prognostic model, which included the
following variables: age and NIHSS. For the secondary endpoint,
i.e. cardioembolic aetiology, the NRI was calculated to assess the
incremental value of BNP over the multivariate model including
age, atrial fibrillation and heart failure. Analyses were performed
using SPSS (SPSS 21, Chicago, IL, USA) and MedCalc (MedCalc
10.4, Mariakerke, Belgium), p-values less than 0.05 were
considered to indicate statistical significance.
Figure 1. Study flow chart.
doi:10.1371/journal.pone.0102704.g001
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Results
Patients
From 605 screened patients, 469 patients were eligible for our
study and 466 completed follow up after 90 days or one year,
respectively. In 362 of the 469 patients ischemic stroke was
diagnosed, while 107 out of the 469 had a TIA. 28 patients were
excluded from the final analysis because BNP and s-cTnI levels
were missing (Figure 1).
Table 1. Baseline characteristics of patients with ischemic stroke and transient ischemic attack.
Baseline characteristics (n = 441)
Demographic findings:
Cerebrovascular re-events, n (%) 27 (6.1)
Death from any cause, n (%) 67 (15.2)
Age, in years 74.6 (62.6–81.9)
Female sex, n (%) 185 (42)
NIHSS at admission, points 5 (2–10)
Charlson score at admission, points 1 (0–2)
ABCD2 score for TIA severity 4 (3–5)
Clinical findings:
Heart rate, in bpm 76 (67–88)
Systolic blood pressure, in mmHg 161 (629)
Diastolic blood pressure, in mmHg 90 (80–100)
Body temperature, in uC 37.0 (60.7)
Laboratory findings:
BNP, in pg/ml 81.9 (35.0–203.3)
Troponin I, in ug/l 0.003 (0.000–0.012)
Glucose, in mmol/L 6.1 (5.3–7.3)
Stroke aetiology, n (%):
Small vessel occlusive 81 (18.4)
Large vessel occlusive 79 (17.9)
Cardioembolic 143 (32.4)
Other 19 (4.3)
Undetermined aetiology 119 (27.0)
Cardiovascular risk factors, n (%):
Hypertension 332 (75.3)
Atrial fibrillation 83 (18.8)
Heart failure 60 (13.6)
Smoking history 154 (34.9)
Dyslipidemia 121 (27.4)
Diabetes mellitus 81 (18.4)
Coronary heart disease 104 (23.6)
Prior TIA or stroke 114 (25.9)
Family history of AMI or stroke 140 (31.7)
Functional outcome (only for stroke patients, n = 344), n (%):
Bad outcome after 90 days 138 (31.3)
Bad outcome after 1 year 141 (32.0)
Clinical stroke syndrome, n (%):
TACS 38 (8.6)
PACS 155 (35.1)
LACS 68 (15.4)
POCS 80 (18.1)
Discrete variables are expressed as frequency (percentage) and continuous Gaussian variables as means with SD and non-Gaussian variables as medians with
interquartile ranges [IQR].
NIHSS = National Institutes of Health Stroke Scale; AMI = acute myocardial infarction; TACS = total anterior circulation syndrome; PACS= partial anterior circulation
syndrome; LACS = lacunar syndrome; POCS = posterior circulation syndrome.
doi:10.1371/journal.pone.0102704.t001
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Baseline demographic and cardiovascular risk factors including
NIHSS and lesion size were not different when comparing patients
with and without available measurements.
Baseline characteristics
The median age was 74.6 (IQR 62.6–81.9) years and 42% were
women. On admission, the median NIHSS in stroke patients was 5
points (IQR 2–10) and median ABCD2 Score in TIA patients was 3
(IQR 3–5). After 90 days, overall 42 patients had died and the
mortality rate was thus 9.5%. After the one-year follow-up, 67
patients had died and the mortality rate was 15.2%. After 90 days 138
(31.3%) of patients with ischemic stroke had an unfavorable outcome
after one year 141 patients (32.0%) of 336 patients with a completed
follow up had an unfavorable outcome (mRS.2). Re-events were
identified in 27 (6.1%) patients with ischemic stroke or TIA.
The principal baseline characteristics of all patients are
provided in Table 1. There were no significant differences
between stroke and TIA patients concerning demographic and
risk factor variables besides the etiologies. In patients with TIA we
found more undetermined etiologies (50.1%) than in patients with
an ischemic stroke (24.0%) (P,0.0001) and in patients with an
ischemic stroke we found more patients with a cardioembolic
source (37.4%) than in patients with a TIA (8%) (p,0.0001).
Main results
Cardiac biomarkers and mortality
Median BNP levels in patients with ischemic stroke or TIA were
81.9 (IQR 35.0–203.3) pg/ml. BNP levels were higher in patients
who died (n= 46) as compared to patients who survived (n= 395)
(309.9 [IQR 162.2–575.8] vs. 69.6 [IQR 31.4–165.3] pg/ml, p,
0.0001) after 90 days. These results were similar for death after
one year (279.0 [IQR 98.4–493.4] vs. 67.8 [IQR 331.4–153.8]
pg/ml, p,0.0001).
Median s-cTnI levels in patients with ischemic stroke or TIA
were 0.003 (IQR 0.000–0.012) mg/L. 310 patients had s-cTnI level
below the detection limit (,0.01 mg/L), 65 patients in the normal
range (0.01–0.027 mg/L), and 66 patients had an increased s-cTnI
level ($0.028 mg/L). Similarly as for BNP, patients who died
showed higher s-cTnI levels as compared to patients who survived
after 90 days and one year (0.015 [IQR 0.0045–0.076] vs. 0.0030
[IQR 0.000–0.0100] mg/L, p,0.0001) and (0.011 [IQR 0.003–
0.055] vs. 0.003 [IQR 0.000–0.010] mg/L, p,0.0001).
In multivariate cox regression analysis BNP but not s-cTnI
remained an independent predictor for death within 90 days with
a hazard ratio (per 100pg/ml unit’s increase) of 1.2 (95% CI 1.1–
1.4). The other independent predictors for death after 90 days
were age and lesion size (see Table 2). Also for long term
mortality (within 1 year) only BNP levels (HR 1.2 (95% CI 1.0–
1.3), age (per 10 years increase) (HR 3.43 (95% CI 1.6–7.3) and
lesion size (HR 1.2 (95% CI 1.0–1.3) remained independent
predictors (see Table 3). In a multivariate analysis including
coronary heart disease, atrial fibrillation and heart failure instead
of the CCI, the hazard ratio of BNP remained similar for 90 days
and for one year (HR 1.2 (95% CI 1.0–1.3) and (HR 1.2 (95% CI
1.0–1.3), respectively) while the other parameters did not remain
significant in the multivariate model.
Table 2. Cox regression analysis for mortality after 90 days for all patients (n = 441).
Univariate Analysis Multivariate Analysis
Variables Hazard ratio (95% Cl) p-value Hazard ratio (95% Cl) p-value
BNP (per 100 pg/ml) 1.2 (1.1–1.2) ,0.001 1.2 (1.1–1.4) 0.007
Troponin I at presentation (per 100 mg/l) 1.0 (1.0–1.0) 0.086
Age (per 10 years) 2.2 (1.5–3.3) ,0.001 3.2 (1.4–7.6) 0.007
Female sex 1.0 (0.5–1.9) 0.965
Systolic blood pressure (per 10 mmHg) 0.9 (0.8–1.0) 0.045
Temperature (per uC) 0.7 (0.4–1.2) 0.23
CRP (per 10 mg/dl) 1.1 (1.0–1.1) 0.001
Glucose (per mmol/l) 1.1 (0.9–1.2) 0.48
NIHSS 1.1 (1.1–1.2) ,0.001 1.1 (1.0–1.2) 0.2
Charlson Score 1.2 (1.0–1.4) 0.02
History of
- Hypertension 1.3 (0.6–2.9) 0.47
- Coronary heart disease 2.0 (1.1–3.9) 0.03
- Heart failure 2.7 (1.3–5.3) 0.006
- Atrial fibrillation 3.0 (1.6–5.7) 0.001
- Dyslipidemia 1.1 (0.6–2.2) 0.75
- Family history of stroke and/or AMI 0.8 (0.4–1.6) 0.49
- Diabetes mellitus 1.3 (0.6–2.7) 0.51
- Smoking 0.9 (0.4–1.7) 0.65
- Prior stroke 0.7 (0.3–1.5) 0.39
Cardioembolic aetiology 1.5 (0.8–2.9) 0.2
Lesion size (per 10 ml) 1.2 (1.1–1.2) ,0.001 1.2 (1.0–1.3) 0.01
CI = confidence interval; CRP = C-reactive protein; NIHSS = National Institutes of Health Stroke Scale; AMI = acute myocardial infarction.
doi:10.1371/journal.pone.0102704.t002
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BNP was predictive also across all subgroups stratified by
presence of atrial fibrillation (HR of BNP among pat with AF 1.16,
p = 0.01 after 90 days and HR 1.14, p = 0.005 after one year
respectively, without AF 1.19, p,0.001 after 90 days and HR
1.18, p,0.001 after one year respectively) or heart insufficiency
(HR of BNP in patients with heart insufficiency 1.12, p,0.001
after 90 days and HR 1.12, p,0.001 after one year respectively,
HR of BNP in patients without heart insufficiency 1.24, p,0.001
after 90 days and HR 1.16, p,0.001 after one year respectively),
thus we found no relevant effect modification.
Moreover the AUC of BNP to predict mortality after 90 days
was 0.81 (95% CI 0.74–0.83) and 0.75 (95% CI 0.68–0.81) after
one year respectively. The comparison of ROC curves of model A
(i.e. the validated prognostic model of Koenig et al [31] including
age and the NIHSS) and model B (age, NIHSS, BNP) revealed an
improvement in the prediction of mortality (AUC 0.85 (95% CI
0.79–0.90) vs. AUC 0.86 (95% CI 0.81–0.92), p = 0.004). The
category free net reclassification improvement (cfNRI) when
adding BNP to the best prognostic model was 57.5%, p,0.0001.
Cardiac biomarkers and functional outcome
For functional outcome only patients with an ischemic stroke
(n = 344) were considered. BNP levels in patients with an
unfavorable outcome after 90 days and after one year were
significantly higher than those in patients with a favorable
outcome (150.0 [IQR 57.3–346.5] vs. 59.9 [IQR 30.2–145.2]
pg/ml, (p,0.0001) for 90 days and 154.1 [IQR 61.5–346.5]
vs.59.9 [IQR 30.2–145.2] pg/mL, (p,0.0001) for one year). S-
cTnI levels were higher in patients with an unfavorable outcome
as compared to patients with a good outcome (0.008 [IQR 0.001–
0.0265] vs. 0.003 [IQR 0.000–0.008] mg/L, (p,0.0001) for 90
days (see Table 4) and 0.008 [IQR 0.001–0.0285] vs. 0.003 [IQR
0.000–0.0105] mg/L, (p = 0.0008) for 1 year) (see Table 5).
However, after adjustment for all other significant outcome
predictors, the only independent outcome predictors were the
NIHSS, age and lesion size (see Table 4 and Table 5).
Cardiac biomarkers and cerebrovascular recurrence
BNP levels in patients with a cerebrovascular re-event were
similar as compared to patients without a re-event (123.3 [IQR
29.4–207.3] vs. 70.4 [IQR 32.9–165.3] pg/ml, p= 0.499).
The same was true for s-cTnI levels (patients with re-event:
0.003 [IQR 0.000–0.010] vs. patients without re-event: 0.004
[IQR 0.000–0.013] mg/L, p = 0.705).
Cardiac biomarkers and cardioembolic aetiology
The aetiology for ischemic stroke or TIA was undetermined in
144 patients (33%), 144 patients (33%) had cardioembolic
aetiology, 76 patients (17%) had large arteriosclerosis, 61 patients
(14%) had a small arteriocclusion and 16 patients (4%) had other
etiologies.
Median BNP levels were higher in patients with a cardioembolic
stroke or TIA compared to other etiologies (179.5 [IQR 72.5–
367.2] vs. 57.2 [IQR 27.5–128.2] pg/ml, p,0.0001). BNP levels
showed an AUC of 0.73 (95% CI 0.68–0.78) to predict a
cardioembolic source of ischemic stroke or a TIA and thus had a
Table 3. Cox regression analysis for mortality after one year for all patients (n = 441).
Univariate Analysis Multivariate Analysis
Variables Hazard ratio (95% Cl) p-value Hazard ratio (95% Cl) p-value
BNP (per 100 pg/ml) 1.2 (1.1–1.2) ,0.001 1.2 (1.0–1.3) 0.02
Troponin I at presentation (per 100 mg/l) 1.0 (1.0–1.0) 0.19
Age (per 10 years) 2.3 (1.4–3.0) ,0.001 3.4 (1.6–7.3) 0.001
Female sex 1.3 (0.8–2.1) 0.39
Systolic blood pressure (per 10 mmHg) 0.9 (0.6–1.0) 0.12
Temperature (per uC) 0.8 (0.5–1.2) 0.25
CRP (per 10 mg/dl) 1.1 (1.0–1.1) 0.023
Glucose (per mmol/l) 1.1 (1.0–1.2) 0.18
NIHSS (per point) 1.1 (1.1–1.2) ,0.001 1.1 (1.0–1.2) 0.2
Charlson Score (per point) 1.3 (1.1–1.4) ,0.001 1.0 (0.8–1.6) 0.6
History of
- Hypertension 1.1 (0.6–2.0) 0.71
- Coronary heart disease 1.6 (0.9–2.8) 0.12
- Heart failure 2.6 (1.5–4.5) 0.001
- Atrial fibrillation 3.3 (2.0–5.5) ,0.001
- Dyslipidemia 0.9 (0.5–1.6) 0.79
- Family history of stroke and/or AMI 0.80(0.5–1.4) 0.42
- Diabetes mellitus 1.0 (0.5–1.9) 0.95
- Smoking 0.6 (0.3–1.0) 0.063
- Prior stroke 0.9 (0.5–1.7) 0.8
Cardioembolic aetiology 1.6 (0.9–2.6) 0.1
Lesion size (per 10 ml) 1.2 (1.1–1.2) ,0.001 1.2 (1.0–1.3) 0.01
CI = confidence interval; CRP = C-reactive protein; NIHSS = National Institutes of Health Stroke Scale; AMI = acute myocardial infarction.
doi:10.1371/journal.pone.0102704.t003
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higher predictive value as compared with age (AUC 0.57 (95% CI
0.51–0.62), p,0.001). The combination of BNP with age, the
history of or newly detected atrial fibrillation and heart failure in
comparison of a nested model had a higher discriminatory
accuracy than age, atrial fibrillation and heart failure alone (AUC
0.79, (95%CI 0.75–0.84) vs. AUC 0.75 (95% CI 0.70–0.80,
p = 0.008 for comparison). The combination of BNP with the
multivariate model led to a category-free net reclassification
improvement (cfNRI) of 48.5% (p,0.001) for cardioembolic
aetiology.
Patients with a cardioembolic source of ischemic stroke had the
highest s-cTnI levels compared to the other etiologies (0.007 [IQR
0.001–0.030] vs. 0.002 [IQR 0.000–0.008] mg/L, p,0.0001). The
AUC of s-cTnI to predict a cardioembolic source was 0.62 (95%
CI 0.56–0.68).
Discussion
In this prospective study we evaluated both, BNP and s-cTnI
levels, in a large cohort of ischemic stroke and TIA patients for
prediction of mortality, functional outcome and re-events after 90
days and 1 year as well as for stroke aetiology.
Our data show the following main findings: First, BNP and s-
cTnI levels on admission were elevated in patients with ischemic
stroke or TIA who had died or had an unfavorable outcome 90
days and one year after the event. After adjustment for other risk
factors BNP but not s-cTnI was an independent predictor of death
but not of functional outcome or recurrence. Second, BNP
improved the identification of patients with cardioembolic strokes
or TIAs when compared to clinical information on admission
alone (i.e. age, CHF and the history of atrial fibrillation).
Our data showing an independent association of BNP with
mortality is mostly in line with findings in the literature. Studies
reported high levels of natriuretic peptides and an association with
mortality in acute stroke patients at admission [11], during
hospitalization [10] and within 6 months [13] after stroke and a
recent meta-analysis concluded that natriuretic peptides are
independent predictors for all cause mortality after stroke [15].
However a recent study found no incremental value of BNP for
the prediction of mortality compared to clinical variables such as
age and NIHSS [11]. This discrepant finding might be due to
methodological differences. The cohort included hemorrhages and
the primary endpoint was mortality or neurological worsening in
the stroke unit, thus within the first days after stroke. There was no
assessment of several potentially influencing medical comorbidities
or of stroke aetiology. In contrast, in our study we assessed only
ischemic stroke and TIA patients and the primary endpoint was
mortality within 90 days and 1 year. Our data contained more
moderate strokes and thus our cohort had a lower level of NIHSS
at admission. We took into account stroke aetiology and several
medical comorbidities which are known to affect mortality and
functional outcome in stroke patients [32]. Importantly, we
adjusted for renal insufficiency (within the CCI), which is known
to affect BNP levels [33].
Data regarding the predictive value of BNP for functional
outcome in patients after a cerebrovascular event are more
controversial. Some studies found an association with functional
outcome [13,34], other studies showed that especially after
Table 4. Logistic regression analysis for functional outcome after 90 days for ischemic stroke patients (n = 342).
Univariate Analysis Multivariate Analysis
Variables OR (95% Cl) p-value OR (95% Cl) p-value
BNP (per 100 pg/ml) 1.2 (1.1–1.3) ,0.001 1.1 (0.9–1.3) 0.26
Troponin I at presentation (per 10 ug/l) 1.0 (1.0–1.0) 0.79
Age 1.1 (1.0–1.1) ,0.001 1.0 (1.0–1.1) 0.07
Female sex 1.6 (1.1–2.5) 0.029 1.0 (0.4–1.1) 0.95
NIHSS (per point) 1.2 (1.1–1.2) ,0.001 1.1 (1.0–1.5) 0.046
Charlson Score (per point) 1.3 (1.1–1.6) ,0.001 1.2 (0.8–1.6) 0.34
Systolic blood pressure (per 10 mmHg) 1.0 (0.9–1.0) 0.29
Temperature (per uC) 0.8 (0.6–1.2) 0.33
Heart beat (per 10/min) 1.1 (1.0–1.3) 0.22
CRP (per 10 mg/dl) 1.1 (1.0–1.2) 0.02 1.0 (0.9–1–2) 0.58
Glucose (per mmol/l) 1.1 (1.0–1.2) 0.21
History of
- Hypertension 1.5 (0.9–2.6) 0.11
- Coronary heart disease 1.3 (0.8–2.1) 0.37
- Heart failure 2.8 (1.5–5.2) 0.001 1.5 (0.4–5.7) 0.56
- Atrial fibrillation 1.9 (1.1–3.2) 0.02 1.1 (0.4–3.0) 0.82
- Dyslipidemia 0.8 (0.5–1.4) 0.43
- Family history of stroke and/or AMI 0.8 (0.5–1.3) 0.29
- Diabetes mellitus 1.2 (0.7–2.0) 0.62
- Smoking 0.8 (0.5–1.2) 0.22
Lesion size (per 10 ml) 1.2 (1.1–1.3) ,0.001 1.2 (1.0–1.3) 0.02
OR= odds ratio; CI = confidence interval; CRP = C-reactive protein; NIHSS = National Institutes of Health Stroke Scale; AMI = acute myocardial infarction.
doi:10.1371/journal.pone.0102704.t004
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adjustment in multivariate analyses BNP did not remain an
independent prognostic marker for functional outcome [11,35].
This is in line with our results. It is biologically plausible since
functional outcome is probably more prominently influenced by
other factors such as brain plasticity. On the other hand,
hemodynamic changes and underlying cardiac disease are major
contributors to mortality after stroke [36].
Data supporting the association of natriuretic peptides with
cardioembolic stroke cumulate. Elevated BNP levels in acute
cerebral infarction were associated with cardioembolic aetiology in
several studies [8,37]. However, the incremental value of BNP
when added to clinical variables, which are known to be associated
with cardioembolic events such as age, has not been evaluated in
these studies. Our data show that the combination of BNP with
age and atrial fibrillation (i.e. history of or a newly diagnosed atrial
fibrillation) had a higher discriminatory accuracy in comparison to
the same model without BNP. BNP may therefore have a role in
risk stratification predicting mortality on one hand and may
support early specific implementation of secondary prevention
such as oral anticoagulants on the other hand.
Midregional proANP (MR-proANP), another natriuretic pep-
tide, was assessed for its predictive role concerning mortality,
functional outcome and cardioembolic aetiology in patients with
an ischemic stroke but not TIA [38]. As BNP, MR- proANP was
an independent predictor of mortality after 90 days and improved
the prognostic value of the NIHSS. Moreover it was also
associated with cardioembolic aetiology improving the diagnostic
accuracy of already known clinical information, such as age,
known heart failure, and known AF on admission. However, BNP
compared to MRproANP is more widely available and clinically
established in most countries and physicians are already familiar
with it. In this study we evaluated BNP with further statistical
methods such as the cfNRI and found a significant improvement
in the prediction even if added to models including not only the
NIHSS but all significant predictors. However a direct comparison
is needed in the future to establish which natriuretic peptide is
better for risk classification and identification of cardioembolic
strokes. In our cohort, s-cTnI was not an independent marker for
all three endpoints. Recently higher Troponin T levels were found
in older patients with a more severe ischemic stroke and with
comorbidities such as heart failure and/or renal insufficiency [39].
Another study showed that elevated levels of high sensitive
Troponin T are frequently present in patients with acute ischemic
stroke but, in accordance to our results, did not provide additional
prognostic information in these subjects [40]. Interestingly s-cTnI
did also not provide additional information for the identification of
cardioembolic aetiology in our study. It may be that s-cTnI is too
specific for myocardial infarction; it is therefore possible that by
measuring s-cTnI levels patients with underlying cardiac disease
not directly due to myocardial damage are missed.
To our knowledge, this is the first study that assesses BNP and s-
cTnI for prediction of stroke recurrence. Our results show that
neither BNP nor Troponin levels were associated with a re-event
after ischemic stroke or TIA. Possibly, these markers have no role
in stroke recurrence. Alternatively, our study was underpowered to
find a significant association with recurrence. Nevertheless our
findings suggest that even if there is an association it is of rather
moderate clinical relevance.
Table 5. Logistic regression analysis for functional outcome after one year for ischemic stroke patients (n = 342).
Univariate Analysis Multivariate Analysis
OR (95% Cl) p-value OR (95% Cl) p-value
BNP (per 100 pg/ml) 1.2 (1.1–1.4) ,0.001 1.1 (1.0–1.3) 0.14
Troponin I at presentation (per 10 ug/l) 1.0 (1.0–1.0) 0.88
Age 1.1 (1.1–1.1) ,0.001 1.1 (1.0–1.1) 0.01
Female sex 1.6 (1.0–2.4) 0.05
NIHSS (per point) 1.1 (1.1–1.2) ,0.001 1.1 (1.0–1.2) 0.01
Charlson Score (per point) 1.4 (1.2–1.6) ,0.001 1.2 (0.9–1.5) 0.29
Systolic blood pressure (per 10 mmHg) 1.0 (0.9–1.0) 0.21
Temperature (per uC) 0.9 (0.6–1.3) 0.44
Heart beat (per 10/min) 1.1 (1.0–1.3) 0.14
CRP (per 10 mg/dl) 1.0 (1.0–1.0) 0.39
Glucose (per mmol/l) 1.0 (0.9–1.1) 0.86
History of
- Hypertension 1.2 (0.7–2.0) 0.46
- Coronary heart disease 1.2 (0.7–2.0) 0.5
- Heart failure 2.5 (1.3–4.7) 0.004 1.7 (0.5–5.6) 0.41
- Atrial fibrillation 2.0 (1.2–3.4) 0.012 1.1 (0.4–2.7) 0.9
- Dyslipidemia 0.7 (0.4–1.2) 0.21
- Family history of stroke and/or AMI 0.5 (0.3–0.9) 0.11
- Diabetes mellitus 1.4 (0.8–2.4) 0.27
- Smoking 0.7 (0.4–1.0) 0.07
Lesion size (per 10 ml) 1.2 (1.1–1.4) ,0.001 1.2 (1.1–1.4) 0.002
OR= odds ratio; CI = confidence interval; CRP = C-reactive protein; NIHSS = National Institutes of Health Stroke Scale; AMI = acute myocardial infarction.
doi:10.1371/journal.pone.0102704.t005
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The following limitations of our study must be taken into
account. First, this was a single center study and further evaluation
and validation in a larger cohort of patients should be performed.
Second, etiological classification is difficult and a large proportion
of patients (especially in the TIA group) remained in the
undetermined category, however no patient was classified in to
this category due to incomplete diagnostic evaluation. Moreover
misclassification might have occurred since at the time of patient
recruitment we performed mainly 24 hours ECG monitoring but
more recent data suggest that longer monitoring increases the
identification of intermittent atrial fibrillation substantially [41,42].
It is therefore possible that we missed some cardioembolic stroke
patients. However, this potential misclassification would lead
rather to a bias towards the null thus underestimating the positive
association. Third, biomarker measurement was performed within
a rather large time frame (i.e. within 72 hours after the event).
However in 398 patients (90%) blood was drawn within 24 hours
of the event, thus it is unlikely that the observed association is only
driven by later measurements. Moreover the predictive value
remained similar when analyzing BNP levels stratified by time
since symptom onset (i.e. 0–3 h, 3–12 h, 12–24 h and 24–72 h)
(data not shown). Finally, the lack of association of cardiac
biomarkers with stroke recurrence may be due to the relative small
number of re-events and thus limited power to find a significant
association.
In conclusion BNP but not s-cTnI is an independent marker
with incremental value for overall mortality prediction but not for
the prediction of functional outcome and re-events in patients with
ischemic stroke or TIA. Furthermore BNP levels contribute
additional information to prior used clinical variables in identify-
ing cardioembolic stroke aetiology. BNP may therefore be helpful
for risk assessment and earlier identification of patients, which may
benefit from oral anticoagulation compared to antiplatelet
therapy. However, further studies are needed to specifically
validate the magnitude of the additional prognostic information,
and to evaluate if this information ultimately leads to an improved
patient care.
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